Pertussis: A disease affecting all ages

American Family Physician

Volumn 74, Issue 3, 2006, Pages 420-426

  Gregory, David S ^a,b  

^a Lynchburg Family Practice Residency   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIHISTAMINIC AGENT; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CLARITHROMYCIN; COTRIMOXAZOLE; DIPHTHERIA TOXOID; ERYTHROMYCIN; IMMUNOGLOBULIN; MACROLIDE; PERTUSSIS VACCINE; STEROID; SULFAMETHOXAZOLE; TETANUS TOXOID; TRIMETHOPRIM;

AIRBORNE INFECTION; BORDETELLA PERTUSSIS; BRAIN DISEASE; CLINICAL FEATURE; DEHYDRATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIARRHEA; DISEASE DURATION; DISEASE TRANSMISSION; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GROUPS BY AGE; HOSPITALIZATION; HUMAN; IMMUNIZATION; INCIDENCE; INFECTION COMPLICATION; INFECTION RISK; NAUSEA; PERTUSSIS; PNEUMONIA; PYLORUS STENOSIS; REVIEW; SEIZURE; SEROLOGY; SLEEP DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; VACCINATION; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE NOTIFICATION; HUMANS; INFANT; MIDDLE AGED; PERTUSSIS VACCINE; UNITED STATES; WHOOPING COUGH;

EID: 33747859664     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005;18:326-82.
2. Centers for Disease Control and Prevention. Pertussis - United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002;51:73-6.
3. Edwards KM. overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J 2005;24(6 suppl):S104-8.
4. Guris D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999;28:1230-7.
5. Hopkins RS, Jajosky RA, Hall PA, Adams DA, Connor FJ, Sharp P, et al. Centers for Disease Control and Prevention. Summary of notifiable diseases - United States, 2003. MMWR Morb Mortal Wkly Rep 2005;52:1-85.
6. Centers for Disease Control and Prevention. National Immunization Program. Pertussis and pertussis vaccine. Epidemiology and prevention of vaccine-preventable diseases [slide presentation]. Accessed August 30, 2005, at: http://www.cdc.gov/nip/ed/slides/pertussis8p.ppt.
7. Centers for Disease Control and Prevention. Pertussis deaths - United States, 2000. MMWR Morb Mortal Wkly Rep 2002;51:616-8.
8. Centers for Disease Control and Prevention. Guidelines for the control of pertussis outbreaks. 2000 (amendments made in 2005 and 2006). Accessed March 21, 2006, at: http://www.cdc.gov/nip/publications/pertussis/guide.htm.
9. Yaari E, Yafe-Zimerman Y, Schwartz SB, Slater PE, Shvartzman P, Andoren N, et al. Clinical manifestations of Bordetella pertussis infection in immunized children and young adults. Chest 1999;115:1254-8.
10. Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics 1997;100:E10. Accessed March 21, 2006, at: http://www.pediatrics.org/ cgi/content/full/100/6/e10.
11. Tozzi AE, Rava L, Ciofi degli Atti ML, Salmaso S, for the Progetto Pertosse Working Group. Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. Pediatrics 2003;112:1069-75.
12. Deeks S, De Serres G, Boulianne N, Duval B, Rochette L, Dery P, et al. Failure of physicians to consider the diagnosis of pertussis in children. Clin Infect Dis 1999;28:840-6.
13. Deen JL, Mink CA, Cherry JD, Christenson PD, Pineda EF, Lewis K, et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis 1995;21:1211-9.
14. De Serres G, Shadmani R, Duval B, Boulianne N, Dery P, Douville FM, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000;182:174-9.
15. Loeffelholz MJ, Thompson CJ, Long KS, Gilchrist MJ. Comparison of PCR, culture, and direct fluorescent-antibody testing for detection of Bordetella pertussis. J Clin Microbiol 1999;37:2872-6.
16. Heininger U, Schmidt-Schläpfer G, Cherry JD, Stehr K. Clinical validation of a polymerase chain reaction assay for the diagnosis of pertussis by comparison with serology, culture, and symptoms during a large pertussis vaccine efficacy trial. Pediatrics 2000;105:E31. Accessed March 21, 2006, at: http://pediatrics.aapublications.org/cgi/content/full/105/3/e31.
17. Edelman K, Nikkari S, Ruuskanen O, He Q, Viljanen M, Mertsola J. Detection of Bordetella pertussis by polymerase chain reaction and culture in the nasopharynx of erythromycin-treated infants with pertussis. Pediatr Infect Dis J 1996;15:54-7.
18. Roush S, Birkhead G, Koo D, Cobb A, Fleming D. Mandatory reporting of diseases and conditions by health care professionals and laboratories. JAMA 1999;282:164-70.
19. Brown Mo, St. Anna L, Ohl M. Clinical inquiries. What are the indications for evaluating a patient with cough for pertussis? J Fam Pract 2005;54:74-6.
20. Pillay V, Swingler G. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev 2003;(4):CD003257.
21. Altunaiji S, Kukuruzovic R, Curtis N, Massie J. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev 2005;(1):CD004404.
22. Pertussis. In: Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, Ill.: American Academy of Pediatrics, 2003:472-86.
23. Halperin SA, Bortolussi R, Langley JM, Miller B, Eastwood BJ. Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections. Pediatrics 1997;100:65-71.
24. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 1999;74:613-34.
25. Aoyama T, Sunakawa K, Iwata S, Takeuchi Y, Fujii R. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr 1996;129:761-4.
26. Langley JM, Halperin SA, Boucher FD, Smith B, for the Pediatric Investigators Collaborative network on Infections in Canada (PICNIC). Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 2004;114:E96-101. Accessed March 21, 2006, at: http://pediatrics.aappublications.org/cgi/content/full/114/1/e96.
27. Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr Infect Dis J 2001;20:1149-54.
28. Tiwari T, Murphy TV, Moran J, for the National Immunization Program, Centers for Disease Control and Prevention. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC guidelines. MMWR Recomm Rep 2005;54(RR-14):1-16.
29. De Serres G, Boulianne N, Duval B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr Infect Dis J 1995;14:969-75.
30. Halperin SA, Bortolussi R, Langley JM, Eastwood BJ, De Serres G. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive Bordetella pertussis infection. Pediatrics 1999;104:E42. Accessed March 21, 2006, at: http://pediatrics.aappublications.org/cgi/content/full/104/4/e42.
31. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24(5 suppl):S58-61.
32. Olin P, Rasmussen F, Gustafsson L, Hallander Ho, Heijbel H, for the Ad Hoc Group for the Study of Pertussis Vaccines. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine [Published correction appears in Lancet 1998;351:454]. Lancet 1997;350:1569-77.
33. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003;21:2003-14.
34. Advisory Committee on Immunization Practices. Centers for Disease Control and Prevention. ACIP recommends adolescent vaccination for tetanus, diphtheria and pertussis vaccine [press release]. Accessed August 30, 2005, at: http://www.cdc.gov/nip/pr/pr_tdap_jun2005.htm.
35. Pichichero ME, Rennels MB, Edwards KM, Blatter MM, Marshall GS, Bologa M, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults [Published correction appears in JAMA 2005;294:3092]. JAMA 2005;293:3003-11.
36. Le T, Cherry JD, Chang SJ, Knoll MD, Lee ML, Barenkamp S, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis 2004;190:535-44.
37. Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, et al., for the APERT Study Group. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005;353:1555-63.
38. Lee GM, LeBaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate? Pediatrics 2005;115:1675-84.
39. Advisory Committee on Immunization Practice. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practice recommends adult vaccination with new tetanus, diphtheria and pertussis vaccine (Tdap) [press release]. Accessed november 15, 2005, at: http://www.cdc.gov/od/oc/media/ pressrel/r051109.htm.